AYTU logo

AYTU BIOPHARMA INC

AYTUNASDAQ
πŸ† #4418 by market capEarnings Feb 2US Equity
$2.66β–² $0.00 (+0.00%)
Market closed Β· at close
πŸ””
Track AYTU
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.0%
7dβ–² 48.6%
14dβ–² 46.6%
30dβ–² 35.4%
ytdβ–² 1.9%
1yβ–² 28.5%
🏦Market Cap
$29M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-13.3%
Declining
πŸ“ŠGross Margin
64.0%
High
πŸ’΅FCF Margin
14.0%
Healthy
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.65 – $2.66
52-Week Range
$1.75 – $3.07
Volume (shares)
148,610
Avg Volume (shares)
β€”
Shares Outstanding
10.9M
Next Earnings
2027-02-02

Fundamentals Snapshot

Annual Revenue
$58M
Last Q Revenue
$16M
P/E Ratio
β€”
P/S Ratio
0.5x
EPS (TTM)
$-1.49
Dividend Yield
β€”
Dilution (1yr)
+22.7%
AYTU logo

AYTU BIOPHARMA INC

AYTU
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$58Mβ–Ό βˆ’13.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.0%β–Ό βˆ’7.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$8Mβ–² +6.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3Mβ–Ό βˆ’163.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.3Mβ–² +22.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About AYTU BIOPHARMA INC

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·5h ago

STOCK ALERT - The M&A Class Action Firm Is Investigating the Merger – AYTU, ADT, CCC and CBNK – IS IT A FAIR DEAL FOR YOU?

NEW YORK, Nov. 22, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the β€œM&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a T

PRNewsWireΒ·4d ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)

NEW YORK, Nov. 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Β (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top

PRNewsWireΒ·4d ago

Are GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

GlobeNewsWireΒ·5d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)

BALA CYNWYD, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

GlobeNewsWireΒ·5d ago

AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.

AYTU shareholders will receive just $2.70 per share in a tender offer transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKE

BenzingaΒ·5d ago

Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket

Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceutica